Comment on “Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis”

Abstract EN

In the recently published article “Early Prognostic Utility of Gp210 AntibodyPositive Rate in Primary Biliary Cholangitis: A Meta-Analysis”, Huang et al.

summarized the published data on autoantibodies anti-gp210, one of the PBC-specific antinuclear antibodies (ANA) with a diagnostic and prognostic values in patients with primary biliary cholangitis (PBC) [1].

Anti-gp210 is indeed the major autoantibody of a family of ANAs directed against proteins of the nuclear pore complex (NPC), but it is widely accepted that the first clear-cut demonstration of the prognostic role of these PBC-specific ANAs comes from an Italian study that focused not only on anti-gp210 but also on anti-NPCs [2–4].

For completeness, we believe that it is important to inform the readers of Disease Markers also about this piece of the story.